- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that it has acquired an exclusive license for the human therapeutic use of a gold-nanoparticle photosensitizer from UCL Business PLC, the technology transfer company of University College London, London, UK.
"In vitro studies have shown that this advanced compound is one of the most potent photodisinfection agents ever developed," stated Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The compound has proven highly efficacious in killing Methicillin/multi-drug Resistant Staphylococcus aureus, (MRSA), a prominent hospital-acquired pathogen. We intend to further develop this new agent for integration into our Photodisinfection System for various medical applications."
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, and an international office in St Michael, Barbados.
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
For more information, please click here
President and Chief Executive Officer
Ondine Biopharma Corporation
The Equicom Group Inc.,
(416) 815-0700 ext. 225
Canaccord Adams Ltd,
Nominated Adviser & Broker
Neil Johnson, Ryan Gaffney
+4420 7050 6500
Copyright © CNW Group Ltd.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stretchy supercapacitors power wearable electronics August 25th, 2016
Semblant to Present at China Mobile Manufacturing Forum 2016 August 25th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Research team led by NUS scientists develop plastic flexible magnetic memory device: Novel technique to implant high-performance magnetic memory chip on a flexible plastic surface without compromising performance July 21st, 2016